Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA320835 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:DNA damage is frequently utilized as the basis for cancer therapies; however, resistance to DNA damage remains one of the biggest challenges facing cancer patients and their treating clinicians. Critically, the molecular drivers behind resistance are poorly understood. To address this question, we created an isogenic model of prostate cancer exhibiting more aggressive characteristics to better understand the molecular signatures associated with resistance and metastasis. 22Rv1 cells were repeatedly exposed to DNA damage daily for 6 weeks, similar to patient treatment regimes. Using Illumina MethylationEPIC arrays and RNA-seq, we compared the DNA methylation and transcriptional profiles between the parental 22Rv1 cell line and the lineage exposed to prolonged DNA damage. Here we show that repeated DNA damage drives the molecular evolution of cancer cells to a more aggressive phenotype and identify molecular candidates behind this process. Total DNA methylation was increased in cells exposed to repeated DNA damage. Further, RNA-seq demonstrated these cells had dysregulated expression of genes involved in metabolism and the unfolded protein response (UPR) with ASNS identified as central to this process. While limited overlap between RNA-seq and DNA methylation was evident, OGDHL was identified as altered in both data sets. Utilising a second approach we profiled the proteome in 22Rv1 cells following a single dose of radiotherapy. This analysis also highlighted the UPR in response to DNA damage. Together, these analyses identified dysregulation of metabolism and the UPR and identified ASNS and OGDHL as candidate genes for resistance to DNA damage. This work provides critical insight into molecular changes which may underpin treatment resistance and metastasis.
2023-04-27 | PXD033400 | Pride
Project description:To investigate the function of ZMYND11 in prostate cancer, we knockdown ZMYND11 in 22Rv1 cells and do RNA-seq.
2024-08-26 | GSE275451 | GEO
Project description:SChLAP1 is a novel long non-coding RNA expressed in prostate cancer. Here we performed transcriptional profiling of the prostate cancer cell lines LNCaP and 22Rv1 comparing non-targeting siRNA treatment versus SChLAP1-siRNA treatment. Goal was to determine the effect of SChLAP1 knockdown on gene expression in prostate cancer. Two-condition experiment: non-targeting siRNA versus SChLAP1 siRNA treated cells. Biological replicates: 1 control replicate, 2 treatment replicates. Technical replicates: 3 replicates per SChLAP1 siRNA. Cell lines: 22Rv1 and LNCaP.
2013-07-20 | E-GEOD-40383 | biostudies-arrayexpress
Project description:We performed microarray analysis using differnt prostate cancer cell lines (PC3 and 22RV1) after TNFRSF13B (CD267) knockdown. We reported that TNFRSF13B regulates cell cycle-associated genes and P53 signaling pathway in PC3 and 22RV1 cells.
2024-02-15 | GSE196746 | GEO
Project description:FoxA1 has been shown critical for prostate development and prostate-specific gene expression regulation. In addition to its well-established role as an AR pioneering factor,several studies have recently revealed significant AR binding events in prostate cancer cells with FoxA1 knockdown. Furthermore, the role of FoxA1 itself in prostate cancer has not been carefully examined. Thus, it is important to understand the role of FoxA1 in prostate cancer and how it interacts with AR signaling. To address these questions, we generated engineered LNCaP cells with FoxA1 knockdown using shRNA or siRNA, 22RV1 cells with stable FoxA1 knockdown and PC3M cells with FoxA1 stable overexpression. We performed microarray analysis of these cells. We performed microarray analysis on LNCaP cells with FoxA1 knockdown using shRNA or siRNA, 22RV1 cells with stable FoxA1 knockdown and PC3M cells with FoxA1 stable overexpression
2013-04-05 | E-GEOD-37314 | biostudies-arrayexpress
Project description:We performed RNA-seq analysis using different prostate cancer cell lines (PC3 and 22Rv1) after morusin treatment. We reported that morusin regulates Akt/mTOR pathway-associated genes in PC3 and 22Rv1 cells. Morusin induces apoptosis and suppresses cell cycle progression, cell migration and invasion in PC3 and 22Rv1 cells.
2024-08-18 | GSE211522 | GEO
Project description:RNA-seq profiling of 22Rv1 prostate cancer cell line either untreated, 6 weeks in culture (age matched) or treated daily for 6 weeks with 1 microgram per ml phleomycin to induce DNA damage (n=3 per sample).
2022-07-18 | GSE208190 | GEO
Project description:SChLAP1 is a novel long non-coding RNA expressed in prostate cancer. Here we performed transcriptional profiling of the prostate cancer cell lines LNCaP and 22Rv1 comparing non-targeting siRNA treatment versus SChLAP1-siRNA treatment. Goal was to determine the effect of SChLAP1 knockdown on gene expression in prostate cancer.
2013-07-20 | GSE40383 | GEO
Project description:Prostate cancer is the most common cancer in men and androgen receptor (AR) downstream signalings promote prostate cancer cell proliferation. PSF is an RNA-binding protein which is involved in AR signaling. To investigate the role of PSF, we performed RNA immunoprecipitation (RIP) and crosslinking immunoprecipitation (CLIP) sequence analysis in AR-positive prostate cancer cell line, LNCaP. In addition, we used hormone-refractory prostate cancer model cells 22Rv1 and long term androgen deprivation (LTAD) cells to explore the differences of PSF function in prostate cancer progression.
2017-12-24 | GSE94243 | GEO